Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kymab

- PMLiVE

Sanofi highlights MS drug data as it swings to a loss in Q4

Reported a €10m net loss in the quarter

Sanofi reception

Sanofi indicted in France over epilepsy drug birth defects

Faces allegations over a failure to warn women about risks associated with drug

- PMLiVE

HIV vaccine based on Sanofi/GSK components fails trial

Data suggested vaccine was no more effective than placebo

Sanofi reception

Sanofi’s rare disease drug olipudase alfa scores in late-stage study

Met crucial endpoints across two clinical studies

- PMLiVE

Sanofi completes acquisition of immuno-oncology specialist Synthorx

Synthorx is now fully owned by the French drugmaker

- PMLiVE

Lilly will aim for one $1bn-$5bn deal per quarter in 2020

Company seeks to bolster pipeline with a string of M&A activity

- PMLiVE

Newly-listed BioNTech buys Neon to boost cell therapy assets

German biotech has agreed to pay $67m in the deal

- PMLiVE

Lilly extends range of cut-price insulins in the US

Announces discounts in response to increasing pricing criticism

- PMLiVE

Galen completes acquisition of healthcare company POA Pharma

Takeover expands Galen's global reach and product portfolio

- PMLiVE

GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

Pricing pressures increase amid intense political scrutiny

Sanofi reception

Sanofi narrows focus, shedding diabetes and cardiovascular research

New CEO Paul Hudson reveals strategy update

- PMLiVE

Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year

Late-stage candidate hit the mark in phase 3 study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links